Nabi to sell Aloprim injection product to Bioniche Teoranta

April 19 (Reuters) - Nabi Biopharmaceuticals (NABI.O) said it agreed to sell its Aloprim for injection product for cancer patients to Ireland-based Bioniche Teoranta for $3.7 million as part of its strategic plan.

As part of the deal, Nabi will receive $1.3 million at closing, $1.4 million at the end of 2007 and $1.0 million at the end of 2008. (Reporting by Jennifer Robin Raj in Bangalore)